Abstract
Here we review the results of physiological, pharmacological, and pathophysiological studies of ATP receptors, P2 type receptors. Characteristics of two families of P2 receptors (P2X and P2Y) are presented and the possibility of using preparations affecting these receptors is discussed.
Similar content being viewed by others
REFERENCES
A. U. Ziganshin and L. E. Ziganshina, Pharmacology of Receptors for ATP [in Russian], Moscow (1999).
M. P. Abbracchio and G. Burnstock, Pharmacol. Ther., 64, 445–475 (1994).
H. J. Agteresch, P. C. Dagnelie, J. W. van den Berg, et al., Drugs., 58, 211–232 (1999).
H. J. Agteresch, P. C. Dagnelie, A. van der Gaast, et al., J. Natl. Cancer Inst. 92, 321–328 (2000).
Y. Aso, A. Tajima, K. Suzuki, et al., Urology., 6, 512–520 (1986).
B. C. Bloor, A. F. Fukunaga, C. Ma, et al., Anesthesiology, 63, 517–525 (1985).
D. J. Boarini, N. F. Kassell, J. A. Sprowell, et al., Neurosurgery, 15, 325–331 (1984).
P. Bodin and G. Burnstock, Inflamm. Res., 47, 351–354 (1998).
J. Bogousslavsky, Cerebrovasc. Dis., 11,Suppl. 2, 5–10 (2001).
G. Buell, G. Collo, and F. Rassendren, Eur. J. Neurosci., 8, 2221–2228 (1996).
G. Burnstock, Pharmacol. Rev., 24, 509–581 (1972).
G. Burnstock, Cell membrane receptors for drugs and hormones: A multidisciplinary approach / Eds. R. W. Straub and L. Bolis, New York (1978) pp. 107–118.
G. Burnstock, Neuropharmacology, 36, 1127–1139 (1997).
G. Burnstock, Prog. Brain Res., 120, 3–10 (1999).
G. Burnstock, Br. J. Anaesth., 84, 476–488 (2000).
G. Burnstock, Drug Dev. Res., 52, 1–10 (2001).
G. Burnstock, Handbook of experimental pharmacology / Eds. M. P. Abbrachio and M. Williams, Berlin (2001) pp. 423–515.
G. Burnstock, Trends Pharm. Sci., 22, 182–188 (2001).
G. Burnstock and M. Williams, J. Pharmacol. Exp. Ther., 295, 862–869 (2000).
G. Burnstock and J. N. Wood, Curr. Opin. Neurobiol, 6,No. 4, 526–532 (1996).
D. A. Cockayne, S. G. Hamilton, Q. M. Zhu, et al., Nature, 407, 1011–1015 (2000).
G. Collo, S. Neidhart, E. Kawashima, et al., Neuropharmacology, 36, 1277–1283 (1997).
B. N. Cronstein, M. G. Bouma, and B. F. Becker, Drug Dev. Res., 39, 426–435 (1996).
R. A. Cunha and J. A. Ribeiro, Life Sci., 68, 119–137 (2000).
F. Di Virgilio, P. A. Borea, and P. Illes, Trends Pharmacol. Sci., 22, 5–7 (2001).
F. Di Virgilio, J. M. Sanz, P. Chiozzi, et al., Prog. Brain Res., 120, 355–370 (1999).
S. J. Dixon and S. M. Sims, Drug Dev. Res., 49, 187–200 (2000).
P. M. Dunn, Curr. Biol., 10, R305–R307 (2000).
P. M. Dunn, Y. Zhong, and G. Burnstock, Prog. Neurobiol., 65, 107–134 (2001).
J. E. Fabre, M. Nguyen, A. Latour, et al., Nat. Med., 5, 1199–1202 (1999).
S. Falzoni, M. Munirati, D. Ferrari, et al., J. Clin. Invest., 95, 1207–1216 (1995).
R. D. Fields and B. Stevens, Trends Neurosci., 23, 625–633 (2000).
B. B. Fredholm, G. Arslan, B. Kull, et al., Drug Dev. Res., 39, 262–268 (1996).
D. Hillaire-Buys, G. Bertrand, J. Chapal, et al., Br. J. Pharmacol., 109, 183–187 (1993).
S. Hourani, F. Di Virgilio and M. M. Loubattieres-Mariani, The P2 nucleotide receptors / Eds. J. T. Turner et al., Totowa (1998) pp. 361–411.
P. P. A. Humphrey, G. Buell, I. Kennedy, et al., Naunyn-Schmiedeberg's Arch. Pharmacol., 352, 585–596 (1995).
B. S. Khakh, E. A. Barnard, G. Burnstock, et al., The IUPHAR compendium of receptor characterization and classification, London (2001) pp. 290–305.
K. Inoue, Pharmacol. Res., 38, 323–331 (1998).
M. F. Jarvis, C. T. Wismer, E. Schweitzer, et al., Br. J. Pharmacol., 132, 259–269 (2001).
B. Jarvis and K. Simpson, Drugs, 60, 347–377 (2000).
K. Kichenin, S. Decollogne, J. Angignard, et al., J. Appl. Physiol., 88, 1962–1968 (2000).
B. F. King, A. Townsend-Nicholson, and G. Burnstock, Trends Pharmacol. Sci., 19, 506–514 (1998).
B. F. King, G. Burnstock, J. L. Boyer, et al., The IUPHAR compendium of receptor characterization and classification, London (2001) pp. 306–320.
O. Korchazhkina, G. Wright, and C. Exley, Br. J. Pharmacol., 127, 701–708 (1999).
T. Matsumoto, T. Nakane, and S. Chiba, Eur. J. Pharmacol., 334, 173–180 (1997).
D. C. B. Mills, Thromb. Haemostas, 76, 835–856 (1996).
K. Mulryan, D. P. Gitterman, C. J. Lewis, et al., Nature, 403, 86–89 (2000).
J. T. Neary, M. P. Rathbone, F. Cattabeni, et al., Trends Neurosci., 19, 13–18 (1996).
R. A. North and A. Suprenant, Ann. Rev. Pharmacol. Toxicol., 40, 563–580 (2000).
S. Palea, W. Artibani, E. Ostardo, et al., J. Urol., 150, 2007–2012 (1993).
S. Palea, C. Pietra, D. G. Trist, et al., Br. J. Pharmacol., 114, 35–40 (1995)
T. M. Palmer and G. L. Stiles, Neuropharmacology, 34, 683–694 (1995).
J. Pintor, A. Peral, B. Navas, et al., Drug Dev. Res., 50, 22 (2000).
E. Rapaport, Ibid, 28, 428–431 (1993).
E. Rapaport, Purinergic approaches in experimental therapeutics / Eds. K. A. Jacobson and M. S. Jarvis, New York (1997) pp. 545–553.
G. A. Rongen, J. S. Floras, J. W. M. Lenders, et al., Clin. Sci., 92, 13–24 (1997).
A. Suprenant, F. Rassendren, E. Kawashima, et al., Science, 272, 735–738 (1996).
R. J. Theobald, Life Sci., 56, 445–454 (1995).
A. Townsend-Nicholson, B. F. King, S. S. Wildman, et al., Brain Res. Mol. Brain Res., 64, 246–254 (1999).
G. Vassort, Physiol. Rev., 81, 767–806 (2001).
C. Z. Wang, N. Numba, T. Gonoi, et al., Biochem. Biophys. Res. Commun., 220, 196–202 (1996).
S. L. Wilbur and F. E. Marchlinski, Am. J. Cardiol., 79,No. 12A, 30–37 (1997).
A. U. Ziganshin, C. H. V. Hoyle, and Burnstock G., Drug Dev. Res., 32, 134–146 (1994).
A. U. Ziganshin, A. P. Zaitcev, N. V. Golovanova, et al., Ibid, 50, 105 (2000).
L. E. Ziganshina, A. U. Ziganshin, C. H. V. Hoyle, et al., Inflamm. Res., 45, 96–102 (1996).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ziganshin, A.U., Ziganshina, L.E. & Burnstock, G. P2 Receptors: Theoretical Background for the Use in Clinical Practice. Bulletin of Experimental Biology and Medicine 134, 313–317 (2002). https://doi.org/10.1023/A:1021921824876
Issue Date:
DOI: https://doi.org/10.1023/A:1021921824876